Compare Boston Scientific Corporation (BSX) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Shell PLC — how do they compare? Boston Scientific Corporation trades at $43.36 (market cap $66.37B), while Shell PLC trades at $84.73 (market cap $230.24B). The key difference: Shell PLC is far larger — about 3.5× Boston Scientific Corporation's market cap, and Shell PLC pays a 3.7% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | SHEL | |
|---|---|---|
Market Cap | $66.37B | $230.24B |
Sector | Health | Energy |
52-Week High | $108.14 | $94.15 |
52-Week Low | $42.63 | $70.28 |
Enterprise Value | $75.94B | $282.77B |
Dividend Yield | — | 3.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Shell (SHEL) trades at $83.98, up 2.13% in the last session, with a bullish technical signal and strong analyst consensus. Recent Q1 2026 earnings beat expectations at $2.44 EPS, while Q2 2026 is projected at $2.88. Valuation metrics appear attractive with a P/E of 13.08 and P/S of 0.92. News highlights include the ARC Resources acquisition approval and Venezuela gas field developments, indicating strategic growth initiatives.
The outlook for SHEL is positive, supported by robust cash flows, a 69% buy rating from analysts, and a consensus price target of $122.20. Risks include declining revenue trends from $381.3B in 2022 to $266.9B in 2025 and geopolitical disruptions in Middle East production. Investors may find value in its dividend yield and LNG market exposure, though macroeconomic volatility remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
